Best Healthcare ETFs for Your Portfolio
Healthcare stocks offer defensive qualities and innovation upside. Here are the top ETFs for sector exposure.
Don't have time? Here's what you need to know:
- 1Healthcare is ~13% of the S&P 500 — you already own it through VTI or VOO
- 2XLV is the default choice: 65 large-cap healthcare stocks, 0.09%, decent yield
- 3Healthcare has defensive qualities — it outperformed during the 2001 and 2008 recessions
- 4Pure biotech ETFs (IBB, XBI) are high-risk satellite plays, not defensive holdings
Healthcare: Defense and Innovation in One Sector
Healthcare is the second-largest sector in the S&P 500 (about 13%). It includes pharmaceutical companies (Johnson & Johnson, Eli Lilly, Pfizer), health insurers (UnitedHealth), medical device makers (Abbott, Medtronic), and biotechnology firms (Amgen, Vertex). The sector has defensive characteristics — people buy medicine regardless of the economy — combined with growth from drug pipelines and innovation.
Healthcare ETFs let you overweight this sector beyond the 13% you already hold through VTI or VOO. Investors often add healthcare for its mix of stability, dividends, and exposure to aging demographics and biotech breakthroughs.
Best Healthcare ETFs Compared
XLV is the most popular choice: low cost, concentrated in the 65 largest healthcare companies, with solid yield and returns. VHT offers broader coverage (400+ stocks) including smaller biotech and medical device companies. IBB and XBI are pure biotech plays — higher risk, higher volatility, lower dividends.
| ETF | Focus | Expense Ratio | Holdings | Yield | 5-Year Return |
|---|---|---|---|---|---|
| XLV | S&P 500 Healthcare | 0.09% | 65 | ~1.6% | ~9% |
| VHT | Total U.S. Healthcare | 0.10% | 400+ | ~1.3% | ~8% |
| IBB | Nasdaq Biotech | 0.44% | 220+ | ~0.2% | ~3% |
| XBI | S&P Biotech (equal-weight) | 0.35% | 140+ | ~0.1% | ~-2% |
| IHI | U.S. Medical Devices | 0.40% | 60 | ~0.3% | ~6% |
When Healthcare ETFs Make Sense
Healthcare is already 13% of VTI. Adding XLV or VHT overweights it. This makes sense if you believe healthcare will outperform due to aging populations, drug innovation, or defensive qualities during economic slowdowns. Healthcare outperformed the S&P 500 during both the 2001 and 2008 recessions.
Keep sector bets small — 5-10% of your total portfolio is a reasonable allocation for a sector tilt. Going above 15% in any single sector increases concentration risk significantly.
Tip: Avoid pure biotech ETFs (IBB, XBI) unless you understand the binary risk: biotech stocks can double on FDA approval or crash 50%+ on drug trial failures. They are not defensive holdings.
Frequently Asked Questions
Is healthcare a good defensive sector?
Yes — healthcare demand is relatively inelastic. People need medicine and doctor visits regardless of the economy. Large-cap healthcare stocks (UnitedHealth, J&J, Pfizer) held up better than the broad market in 2008 and 2020. Biotech is the exception — it is not defensive.
XLV or VHT — which is better?
XLV is more concentrated in large-cap healthcare (65 stocks) with a lower expense ratio. VHT is broader (400+ stocks) including smaller biotech and device companies. For large-cap stability, XLV. For broader healthcare coverage, VHT.
Do I need a healthcare ETF if I own VTI?
No — VTI already holds all healthcare stocks at market weight. A healthcare ETF is an intentional sector overweight. Only add one if you have conviction in the sector's outperformance and keep it under 10% of your portfolio.
Further Reading
Free Tools
Alex Harrington
CFA Level II Candidate, Finance & Economics
Alex Harrington is an independent ETF researcher and personal finance writer with over 8 years of experience analyzing exchange-traded funds. A CFA Level II candidate with a background in economics, Alex has reviewed 800+ ETFs and helped thousands of beginners build their first investment portfolios through clear, jargon-free education.
This content is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Consult a licensed financial advisor before making investment decisions.